Bio-Techne Corp
NASDAQ:TECH
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
Bio-Techne Corp
NASDAQ:TECH
|
US |
|
B
|
Bankinter SA
XMUN:BAKA
|
ES |
|
Speed Commerce Inc
OTC:SPDC
|
US |
|
Gofore Oyj
F:1E2
|
FI |
|
A
|
AppliCAD PCL
SET:APP
|
TH |
|
I
|
INPAQ Technology Co Ltd
TPEX:6284
|
TW |
|
Maja Agung Latexindo PT Tbk
IDX:SURI
|
ID |
|
Mineral Road Discovery Inc
F:7C9
|
CA |
|
C
|
Chemtronics Co Ltd
KOSDAQ:089010
|
KR |
|
C
|
Carilex Medical Inc
TPEX:7726
|
TW |
|
A
|
Artisan Partners Asset Management Inc
F:AP0
|
US |
|
I
|
Innodisk Corp
TPEX:5289
|
TW |
|
EnviroMetal Technologies Inc
OTC:EVLLF
|
CA |
|
C
|
Chocoladefabriken Lindt & Spruengli AG
DUS:LSPN
|
CH |
|
Cassiar Gold Corp
XTSX:GLDC
|
CA |
|
H
|
Hove A/S
F:LL0
|
DK |
|
M
|
Microlink Solutions Bhd
KLSE:MICROLN
|
MY |
|
S
|
S4 Capital PLC
OTC:SCPPF
|
UK |
|
D
|
Del Monte Corp
DUS:FDM
|
KY |
|
Bank of the Philippine Islands
OTC:BPHLF
|
PH |
|
G
|
Gemlife Communities Group
ASX:GLF
|
AU |
|
M
|
Montego Resources Inc
OTC:MONGF
|
CA |
|
P
|
Parazero Technologies Ltd
NASDAQ:PRZO
|
IL |
|
Lomiko Metals Inc
OTC:LMRMF
|
CA |
Ergebniskonferenzen
Letzter Earnings Call
Revenue: Bio-Techne reported Q3 revenue of $311.4 million, down 2% year over year, with underlying organic growth of 2% after adjusting for timing and other one-time items.
Margins: Adjusted operating margin was 34.2%, up 310 basis points sequentially, showing strong profitability even in a mixed demand environment.
Biotech Weakness: Emerging biotech spending was softer than expected and declined high single digits, which management said was the main reason the quarter came in below its underlying trend.
Strong Spots: Large pharma grew low double digits for its sixth straight quarter, China posted its fourth consecutive quarter of organic growth, and Spatial Biology delivered mid-teens growth.
Outlook: Management expects Q4 organic growth to be approximately flat, with low single-digit underlying growth excluding the temporary cell therapy headwind.
FY27 View: Management said it would be disappointed not to deliver at least mid-single-digit growth in fiscal 2027, citing improving biotech funding, a steadier academic market and easier comparisons.